Evolution of economic evidence use in drug pricing decisions in Jordan : using a standardized pharmacoeconomic checklist to inform value-based decisions

Tools

Mousa, Rimal and Hammad, Eman and Melhem, Samar and Balkhi, Bander and Kurdi, Amanj and Massad, Eman (2026) Evolution of economic evidence use in drug pricing decisions in Jordan : using a standardized pharmacoeconomic checklist to inform value-based decisions. Health Policy and Technology, 15 (6). 101222. ISSN 2211-8837 (https://doi.org/10.1016/j.hlpt.2026.101222)

[thumbnail of Mousa-etal-HPT-2026-Evolution-of-economic-evidence-use-in-drug-pricing]
Preview
 Text. Filename: Mousa-etal-HPT-2026-Evolution-of-economic-evidence-use-in-drug-pricing.pdf
Accepted Author Manuscript
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Objectives This study evaluated the methodological and reporting quality of economic evaluation (EE) submissions to the Jordan Food and Drug Administration (JFDA) pricing committee before and after the implementation of a standardized pharmacoeconomic checklist in October 2022. Methods This study employed a retrospective longitudinal design, analyzing all applications submitted to the JFDA drug pricing committee between April 2022 and January 2024. The quality scores of the EE reporting and the type of study were analyzed and compared before and after the implementation of the pharmacoeconomic checklist. Improvement percentages of methodological reporting and the applicability quality of the cost-effectiveness (CE) evidence were compared between the pre- and post-checklists. Results A total of 271 pricing applications were reviewed. Before the implementation of the JFDA checklist, only 1.7% of applications (2/117) required and submitted CE evidence; following the checklist, this increased to 8.4% (13/154). The applicability of CE submissions improved markedly from 28% pre-checklist to 71% post-checklist. Methodological quality also improved across most domains, including the use of appropriate treatment-effect data, which increased from 33% to 70, and the inclusion of sensitivity analyses rose from 33% to 60%. However, notable gaps persisted, particularly the limited availability of local baseline epidemiological and cost data. Conclusion The findings demonstrate improvements in the rigor, transparency, and contextual relevance of the EEs submitted after the implementation of the checklist. This represents a step toward more structured and value-based pricing decisions in Jordan. Ongoing local data generation and sharing will be essential to sustain progress toward value-based pricing in Jordan.

ORCID iDs

Mousa, Rimal, Hammad, Eman, Melhem, Samar, Balkhi, Bander, Kurdi, Amanj ORCID logoORCID: https://orcid.org/0000-0001-5036-1988 and Massad, Eman;
CORE (COnnecting REpositories)